Clinical trials: Demyelinating Autoimmune Diseases, CNS
Multiple Sclerosis
A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
- Trial name
- NCT01318421
- Testing
- ELND002
- Volunteers
- 12 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
- Trial name
- ENCORE (NCT01167426)
- Testing
- Glatiramer Acetate 20 mg/0.5 mL
- Volunteers
- 148 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis, Relapsing-Remitting
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
The primary objective(s) of the study are to assess the BG00012 (dimethyl fumarate) treatment effect on cognition over 2 year period in RRMS patients.
- Trial name
- StarTec (NCT02579681)
- Testing
- dimethyl fumarate
- Where
- 18 sites in Italy
- Volunteers
- 221 people
- Sponsor
- Biogen
Multiple Sclerosis
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.
- Trial name
- NCT00381264
- Testing
- Cesamet™ (nabilone)
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- NEMA Research, Inc.
Multiple Sclerosis
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Vaccine responses in patients treated with anti-CD20 antibodies (ocrelizumab and ofatumumab) or S1P receptor modulators (fingolimod and siponimod) were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing…
- Trial name
- NCT05950308
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS).
- Trial name
- CHANGE-MS (NCT02782858)
- Testing
- GNbAC1
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 270 people
- Sponsor
- GeNeuro SA
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Multiple Sclerosis
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS.
- Trial name
- NCT00395317
- Testing
- Firategrast 150 mg, Firategrast 300 mg
- Where
- 79 sites in Australia, Austria and 12 more
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
ATX-MS-1467 in Multiple Sclerosis
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of…
- Trial name
- NCT01973491
- Testing
- ATX-MS-1467
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH
Multiple Sclerosis
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
This was a retrospective cohort study utilizing the IQVIA PharMetrics® Plus claims database from 01 August 2019 through 31 May 2022.
- Trial name
- NCT06644638
- Where
- United States
- Volunteers
- 3,632 people
- Sponsor
- Novartis
Multiple Sclerosis
Dimethyl Fumarate (DMF) Observational Study
The primary objective of the study is to determine the incidence, type, and pattern of serious adverse events (SAEs), including but not limited to infections (including opportunistic infections), hepatic events, malignancies, and…
- Trial name
- ESTEEM (NCT02047097)
- Testing
- dimethyl fumarate
- Where
- 468 sites in United States, Argentina and 20 more
- Volunteers
- 5,487 people
- Sponsor
- Biogen